D3 Bio (Wuxi)

D3 Bio (Wuxi), based in Wuxi, China, is a biotechnology company. D3 Bio is a private, clinical-stage biotechnology company developing precision oncology and immunology medicines targeting immune pathways and tumour-driving mutations. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials. The largest, NCT05410145 (A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumours With a KRAS p.G12C Mutation), plans to enrol 442 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website. Its website describes D3S-001 as a next-generation KRAS G12C-selective inhibitor for non-small-cell lung and colorectal cancers with that mutation, and D3S-003 as a KRAS G12D inhibitor.